Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. The Pan-American Collaborative Retina Study Group at 24 Months

"Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin; Genentech, Inc., San Francisco, CA; 1.25 or 2.5 mg) in patients with diffuse diabetic macular edema (DDM...

Descripción completa

Detalles Bibliográficos
Autores Principales: Arevalo, J. Fernando, Sanchez, Juan G., Wu, Lihteh, Maia, Mauricio, Alezzandrini, Arturo A., Brito, Miguel, Bonafonte, Sergio, Lujan, Silvio, Diaz-Llopis, Manuel, Restrepo, Natalia, Rodríguez, Francisco J., Udaondo-Mirete, Patricia, Group, Pan-American Collaborative Retina Study
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Elsevier Inc. 2009
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/22731
https://doi.org/10.1016/j.ophtha.2009.03.016